

CHICAGO CLINICAL RESEARCH STUDIES

Study	Title	Condition	Intervention	Location (s)	Study URL
1	Lupus Intervention for Fatigue Trial (LIFT)	Fatigue, Physical Activity, Systemic Lupus	Behavioral: Experimental Other: Control	Holly Milaeger, Chicago, Illinois, United States	https://ClinicalTrials.gov/ct2/show/NCT02653287
				Northwestern University, Chicago Illinois, United States	
2	A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)	Systemic Lupus Erythematosus	Drug: DZP Other: Placebo	SI0043 50310, Chicago, Illinois, US. SI0043 50360, Skokie, Illinois, US	https://ClinicalTrials.gov/ct/show/NCT04294667
3	Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus	Active Systemic Lupus Erythematosus	Drug: Efavaleukin Alfa Drug: Placebo Other: Standard of Care	Clinic of Robert Hozman, MD - Clinical Investigational Specialists, Inc, Skokie, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT04680637
				Greater Chicago Specialty Physicians, Schaumburg, Illinois, United States	
4	Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE)	Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome	Observational: To identify mechanisms and predictors of poor fetal outcome	Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT00198068
				University of Chicago, Chicago, Illinois, United States	
5	Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V	Lupus Nephritis	Drug: Iptacopan (part 1) Drug: Iptacopan (part 2) Drug: Placebo + standard of care Drug: Iptacopan + placebo	Novartis Investigative Site. Hinsdale, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT05268289

CHICAGO CLINICAL RESEARCH STUDIES

Study	Title	Condition	Intervention	Location (s)	Study URL
6	Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)	Systemic Lupus Erythematosus	Drug: Low Dose Mesenchymal Stem Cells (MSCs) Drug: High Dose Mesenchymal Stem Cells (MSCs) Drug: Placebo Infusion	Northwestern University. Chicago, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT02633163
7	VIBRANT: VIB4920 for Active Lupus Nephritis	Lupus Nephritis	Drug: VIB4920 Drug: Placebo for VIB4920	University of Chicago, Department of Medicine: Rheumatology, Chicago, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT05201469
8	Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus (DIVERT)	Systemic Lupus Erythematosus	Drug: Mycophenolate Mofetil Drug: Placebo for Mycophenolate Mofetil Drug: Voclosporin Drug: Placebo for Voclosporin	University of Chicago, Department of Medicine: Rheumatology, Chicago, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT05306873
9	A Study to Evaluate the Continuous Safety and Efficacy of BIIB059 in Adults With Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: BIIB059 Drug: BIIB059-matching placebo	Research Site, Chicago, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT05352919
10	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)	Lupus Nephritis	Drug: Obinutuzumab Drug: MMF Drug: Prednisone (and 4 more...)	Northwestern University, Chicago, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT04221477
11	A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus	Drug: Afimetoran Other: Placebo	Greater Chicago Specialty Physicians - Orland Park, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT04895696
12	ALPN-101 in Systemic Lupus Erythematosus (Synergy)	Systemic Lupus Erythematosus	Drug: ALPN-101 Drug: Placebo	Skokie, Illinois, United States, Investigational Site (107)	https://ClinicalTrials.gov/ct/show/NCT04835441
13	Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus (SLE)	Drug: Rozibafusp Alfa Drug: Placebo for Rozibafusp Alfa	Clinic of Robert Hozman, MD - Clinical Investigational Specialists, Inc, Skokie, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT04058028

CHICAGO CLINICAL RESEARCH STUDIES

Study	Title	Condition	Intervention	Location (s)	Study URL
14	Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)	Lupus Nephritis	Drug: Secukinumab	Medical College of Wisconsin, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/ct/show/NCT04181762
15	Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)	Lupus Nephritis, Immunoglobulin A Nephropathy	Drug: Ravulizumab Drug: Placebo Other: Background Therapy	Clinical Study Site, Milwaukee, Wisconsin, United States	https://ClinicalTrials.gov/ct/show/NCT04564339
16	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis	Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome	Drug: Branebrutinib Drug: Abatacept Drug: Branebrutinib placebo	Clinical Investigation Specialists - Gurnee, Skokie, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT04186871
17	Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Advanced Malignant Solid Neoplasm, Autoimmune Disease, Crohns Disease, (and 11 more...)	Biological: Nivolumab	Northwestern University Chicago, Illinois, United States	https://ClinicalTrials.gov/ct/show/NCT03816345

If you think you may be a candidate to participate in a clinical trial, then consider taking the information back to your loved ones and personal physician and have a very serious conversation with them. Making the choice to participate in a clinical trial is not only a major decision, but a very personal one that should be based on discussions with your family members and treating physicians familiar with your history. We cannot emphasize this strongly enough.